Drugs / Silibinin
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03687073 | Nov 2018 → May 2021 | — | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT01129570 | Feb 2010 → Jun 2013 | hepatocellular carcinoma | Abby Siegel | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT01816490 | Apr 2013 → Apr 2014 | HIV infectious disease, chronic hepatitis C virus infection | University of Zurich | Completed | No outcome recorded |
| Phase 2 | NCT01518933 | Aug 2011 → Apr 2012 | hepatitis C virus infection | Rottapharm | Terminated | No outcome recorded |
| Phase 2 | NCT01265563 | Jan 2011 → Feb 2015 | diabetic kidney disease, disorder of defective peroxisome oxidative status, proteinuria | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2 | NCT01535092 | Sep 2010 → Oct 2011 | — | Rottapharm | Terminated | No outcome recorded |
| Phase 2 | NCT00915681 | Nov 2009 → Apr 2020 | liver failure, mycotoxicosis | Mylan Specialty, LP | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00684268 | Oct 2007 → Feb 2011 | chronic hepatitis C virus infection | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT00487721 | Aug 2006 → Sep 2007 | prostate cancer | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03538327 | Oct 2013 → Apr 2014 | essential hypertension | University Magna Graecia | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 0 | NCT05523648 Background | Jan 2020 → Dec 2021 | NAFLD1, chronic hepatitis B virus infection | Sichuan Leshan Traditional Chinese Medicine Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03216668 Comparator | Jun 2017 → Jun 2019 | liver failure | Nhat Nhat Pharmaceutical Company | Unknown | No outcome recorded |
| Phase 3 | NCT01935817 Comparator | Jun 2010 → Dec 2012 | fibrotic liver disease | University of Catania | Completed | No outcome recorded |
| Phase 3 | NCT01957319 Comparator | Feb 2010 → Jul 2013 | depressive disorder | University of Catania | Completed | No outcome recorded |
| Phase 4 | NCT02347319 Comparator | Apr 2012 → May 2013 | liver disorder | PharmaKing | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Silibinin | “The control group was treated with silibinin meglumine tablets and tenofovir, while the treatment group was treated with Ganshuang granules combined with silybin meglumine...” PMID 36588741 ↗ Dec 20227“Silibinin is a polyphenolic flavonolignan derived from milk thistle (Silybum marianium) with anti-oxidant properties.” PMID 20127732 ↗ Jun 2010 |
| Known as | iSIL | “Intravenous Silibinin (iSIL)” NCT01816490 ↗ |
| Known as | ivSIL | “Intravenous silibinin (ivSIL) is a potent antiviral agent against HCV.” PMID 22155914 ↗ 2011 |
| Known as | Legalon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02347319 ↗ |
| Known as | Legalon Sil | “First, 16 patients received 10 mg/kg/day SIL IV (Legalon Sil; Madaus, Köln, Germany) for 7 days.” PMID 18771667 ↗ Aug 2008 |
| Known as | Realsil | “it was also recommended to take silybin coniugated to vitamin E and phosphatidylcholine that shows higher intestinal absorption and bioavailability (Indena, IBI-Lorenzini spa...” NCT03538327 ↗ |
| Known as | SIL | “Oral Silibinin (SIL) is widely used for treatment of hepatitis C, but its efficacy is unclear.” PMID 18771667 ↗ Aug 2008 |
| Known as | silibin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01265563 ↗ |
| Known as | Silybin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01935817 ↗ |
| Action | Inhibit | “In vitro silibinin (SIL) inhibits viral replication, possibly by inhibiting HCV RNA polymerase.” PMID 22155914 ↗ 2011 |
| Modality | Small molecule | “Silibinin, a flavonolignan representing the main component (60%) of Silymarin” NCT01518933 ↗ |
| Route | Oral | “High-dose oral silybin-phytosome achieves high blood concentrations transiently, but low levels of silibinin are seen in prostate tissue.” PMID 20127732 ↗ Jun 2010 |
| Target | TNF | “Silibinin is able to inhibit Tumor necrosis factor-alpha (TNF-α).” NCT01518933 ↗ |